The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.
The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback